Ecstasy could become prescription for PTSD after final FDA trial

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

Ecstasy, also known as “molly,” is an illegal, unregulated party drug which often runs rampant in the nightlife crowd.

A substance called MDMA found within the illegal drug has shown promise in previous trials in treating post traumatic stress disorder.

Those trials showed MDMA-assisted psychotherapy had a dramatic improvement with veterans, emergency responders, law enforcement, and victims of violent crimes, all who had seen no change after years of traditional treatment.

By the end of those studies, researchers say two-thirds of the participants showed no signs of PTSD and the effects lasted up to a year.

Now the FDA has just approved a large-scale Phase 3 clinical trial.

That trial will determine whether Ecstasy will eventually become a prescription drug.

The head of psychiatry at Langone School of Medicine, Dr. Charles R. Marmar, tells The New York Times, “If they can keep getting good results, it will be of great use. PTSD can be very hard to treat. Our best therapies right now don’t help 30 to 40 percent of people, so we need more options.”

However, Marmar also says he’s concerned that the feel-good drug could also lead to abuse.

However, the drug would only be administered to each patient in the presence of a trained psychotherapist, in conjunction with other forms of talk therapy.

The FDA is prohibited to talk about drugs that are currently under development.

If approved after the final trial, the new prescripTWO tion drug could be available by the year 2021.

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.